BioStem Q2 revenue $7.9M (up 29% QoQ), net loss $9.0M, raises FY26 guide

BioStem Technologies, Inc.

2026-Q2 EPS reported -$1.04 vs consensus -$0.51 ▼ miss (-103.9%)

Q2 2026 net revenue $7.9M vs $6.1M Q1 2026 (+29%) and $11.0M Q2 2025; hospital $6.7M, physician $1.1M.
GAAP net loss $9.0M ($0.52/share) vs income $10,613 in Q2 2025; adjusted EBITDA loss $4.6M.
Cash $7.0M at June 30, 2026 (from $13.7M); used $5.5M in ops; closed $2.5M private placement.
Resolved $5.3M debt via $3.5M cash and $1.0M promissory note; uplisted to Nasdaq Capital Market Aug 7, 2026.
Raises FY2026 revenue guidance to $26-29M from $25-29M; issued eight new U.S. design patents.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.